@article{556095c64aee47a09f66f8adf178d237,
title = "Seroprevalence of Measles Antibodies in a Highly MMR-Vaccinated Population",
abstract = "As an extremely contagious pathogen, a high rate of vaccine coverage and the durability of vaccine-induced immunity are key factors to control and eliminate measles. Herein, we assessed the seroprevalence of antibodies specific to measles in a cohort of 1393 adults (20–44 years old). ELISA results showed a nontrivial proportion of 37.6% study subjects being negative for measles immunoglobulin G (IgG). We also found significant influences of sex and age of the study cohort on the IgG level. Our findings suggest that even within a highly vaccinated population, a subset of individuals may still have sub-optimal immunity against measles and potentially be susceptible during any future measles outbreaks.",
keywords = "measles virus, MMR vaccine, seroprevalence, serosurveillance, waning immunity",
author = "Quach, {Huy Quang} and Ovsyannikova, {Inna G.} and Grill, {Diane E.} and Warner, {Nathaniel D.} and Poland, {Gregory A} and Kennedy, {Richard B.}",
note = "Funding Information: Research reported in this publication was supported by the National Institute of Allergy, Infectious Diseases of the National Institutes of Health and National Institute of Allergy and Infectious Diseases under awards: R01 AI127365, R01 AI121054, and R01 AI33144. Funding Information: Poland offers consultative advice to Johnson & Johnson/Janssen Global Services LLC, and is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Poland also offers consultative advice on vaccine development to Merck & Co (Keniworth, NJ, USA)., Medicago (Quebec City, Quebec, Canada), GlaxoSmithKline (Brentford, United Kingdom), Sanofi Pasteur (Lyon, France), Emergent Biosolutions (Gaithersburg, MD, USA), Dynavax (Emeryville, CA), Genentech (South San Francisco, CA, USA), Eli Lilly and Company (Indianapolis, IN, USA), Kentucky Bioprocessing Inc. (Owensboro, KY, USA), Bavarian Nordic (Hellerup, Denmark), AstraZeneca (Cambridge, United Kingdom), Exelixis (Alameda, CA, USA), Regeneron (Tarrytown, NY, USA), Janssen (Beerse, Belgium), Vyriad (Rochester, MN, USA), Moderna (Cambridge, MA, USA), and Genevant Sciences, Inc. (Cambridge, MA, USA). Poland and Ovsyannikova hold patents related to vaccinia and measles peptide vaccines. Drs. Kennedy, Poland, and Ovsyannikova hold a patent related to vaccinia peptide vaccines. Poland, Kennedy, and Ovsyannikova have received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. Kennedy has received funding from Merck Research Laboratories to study waning immunity to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policy. Funding Information: We would like to thank all of the participants in this study. We would also like to thank Emily A. Voigt for the assessment of measles antibody titers. We are grateful to financial support from NIAID. Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
month = nov,
doi = "10.3390/vaccines10111859",
language = "English (US)",
volume = "10",
journal = "Vaccines",
issn = "2076-393X",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",
}